Please assess the completion status of the following clinical trial:

Trial Title: ALTA-1L Study: A Study of Brigatinib Versus Crizotinib in Anaplastic Lymphoma Kinase Positive (ALK+) Advanced Non-small Cell Lung Cancer (NSCLC) Participants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Have histologically or cytologically confirmed stage IIIB (and not a candidate for definitive multimodality therapy) or stage four (IV) NSCLC.~2. Must have documented ALK rearrangement.~3. Have sufficient tumor tissue available for central analysis.~4. Have at least 1 measurable (that is, target) lesion per RECIST v1.1.~5. Recovered from toxicities related to prior anticancer therapy to National Cancer Institute (of the United States) (NCI) Common Terminology Criteria for Adverse Events (version 4.0) (CTCAE v 4.0) grade be less than or equal to (\<=) 1.~6. Are a male or female participants greater than or equal to (\>=)18 years old.~7. Have adequate organ function, as defined by the study protocol.~8. Have Eastern Cooperative Oncology Group (ECOG) performance status \<=2.~9. Have normal QT interval on screening ECG evaluation, defined as QT interval corrected (Fridericia) (QTcF) of \<= 450 millisecond (msec) in males or \<=470 msec in females.~10. For female participants of childbearing potential, have a negative pregnancy test documented prior to randomization.~11. For female and male participants who are fertile, agree to use a highly effective form of contraception, as defined by the study protocol.~12. Provide signed and dated informed consent indicating that the participants has been informed of all pertinent aspects of the study, including the potential risks, and is willingly participating.~13. Have the willingness and ability to comply with scheduled visit and study procedures.~Exclusion Criteria:~1. Previously received an investigational antineoplastic agent for NSCLC.~2. Previously received any prior tyrosine kinase inhibitor (TKI), including ALK-targeted TKIs.~3. Previously received more than 1 regimen of systemic anticancer therapy for locally advanced or metastatic disease.~4. Received chemotherapy or radiation within 14 days of first dose of study drug, except stereotactic radiosurgery (SRS) or stereotactic body radiation therapy (SBRT).~5. Received anti-neoplastic monoclonal antibodies within 30 days of the first dose of study drug.~6. Had major surgery within 30 days of the first dose of study drug, minor surgical procedures such as catheter placement or minimally invasive biopsies are allowed.~7. Have been diagnosed with another primary malignancy other than NSCLC, except for adequately treated non-melanoma skin cancer or cervical cancer in situ; definitively treated non-metastatic prostate cancer; or participants with another primary malignancy who are definitively relapse-free with at least 3 years elapsed since the diagnosis of the other primary malignancy.~8. Have symptomatic CNS metastases (parenchymal or leptomeningeal) at screening or asymptomatic disease requiring an increasing dose of corticosteroids to control symptoms within 7 days prior to randomization.~9. Have current spinal cord compression (symptomatic or asymptomatic and detected by radiographic imaging). Participants with leptomeningeal disease and without cord compression are allowed.~10. Be pregnant, planning a pregnancy, or breastfeeding.~11. Have significant, uncontrolled, or active cardiovascular disease, as defined by the study protocol.~12. Have uncontrolled hypertension.~13. Have a history or the presence at baseline of pulmonary interstitial disease, drug-related pneumonitis, or radiation pneumonitis.~14. Have an ongoing or active infection.~15. Have a known history of human immunodeficiency virus (HIV) infection.~16. Have a known or suspected hypersensitivity to brigatinib or its excipients and/or crizotinib or its excipients.~17. Have malabsorption syndrome or other gastrointestinal (GI) illness or condition.~18. Have any condition or illness that, in the opinion of the investigator, would compromise participant's safety or interfere with the evaluation of the study drug.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Randomized Phase: Brigatinib 90 mg QD/180 QD (Type: EXPERIMENTAL): Brigatinib 90 mg, tablets, orally, QD for first 7 days followed by 180 mg, orally, QD, in each 28-day cycle until PD, intolerable toxicity, consent withdrawal, or death (The median duration of exposure was 34.86 months).
- Randomized Phase: Crizotinib 250 mg BID (Type: ACTIVE_COMPARATOR): Crizotinib 250 mg, tablets, BID in each 28-day cycle until disease progression, intolerable toxicity, consent withdrawal, or death (The median duration of exposure was 9.26 months).
- Crossover Phase: Brigatinib 90 mg QD/180 mg QD (Type: EXPERIMENTAL): Participants who experienced PD as assessed by the BIRC or received radiotherapy to the brain while on 'Crizotinib 250 mg BID' therapy in Randomized Phase were crossed over. Following 10-day washout period, crossover participants received brigatinib 90 mg, tablets, orally, QD for first 7 days followed by 180 mg, tablets, orally, QD in each 28-day cycle up to end of the study (The median duration of exposure was 17.25 months).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete